Drug Pricing in South Korea

Applied Health Economics and Health Policy

Volumn 15, Issue 4, 2017, Pages 447-453

  Kwon, Hye Young ^a   Godman, Brian ^b,c  

^a Mokwon University   (South Korea)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NEW DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; REIMBURSEMENT; SOUTH KOREA; COST CONTROL; HEALTH CARE POLICY; HUMAN;

COST CONTROL; DRUG COSTS; HEALTH POLICY; HUMANS; REPUBLIC OF KOREA;

EID: 85010930984     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-017-0307-0     Document Type: Article

References (35)

1. Ministry of Health and Welfare. Statistics for National Health Insurance and Health Policy. Seoul 2014.
2. Ministry of Health and Welfare. Drug expenditure rationalization plan (DERP). Press release May 03, 2006. Available at: http://www.mw.go.kr/front/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SEQ=37687&page=1&SEARCHKEY=TITLE&SEARCHVALUE. Accessed 17 May 2016.
3. Kwon HY, Kim HM, Godman B, Reich M. The impact of South Korea’s new drug-pricing policy on market competition among outpatient drugs. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):1007–14.
4. National Health Insurance Service. History of the Korean national health insurance. Available at http://www.nhis.or.kr/menu/retriveMenuSet.xx?menuId=B2160 (accessed on 28 July 2016). Accessed 17 June 2016.
5. Jeong HS, Sin JW. Debates on the national health insurance coverage and international comparison. HIRA policy brief 2011; March 17–27.
6. OECD. Pharmaceutical expenditure. Health: Key tables from OECD, No. 7. doi:10.1787/pharmexptable-2014-1-en. Accessed 17 June 2016.
7. Bae EY, Hong JM, Kwon HY, et al. Eight-year experience of using HTA in drug reimbursement: South Korea. Health Policy. 2016;120(6):612–20.
8. Ministry of Health and Welfare. Enforcement regulations of national health insurance. Raw article 10-2. Application of drug reimbursement decision no. 404; June 03, 2014.
9. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
10. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: The European experience: LSE; 2013 [cited]. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/mea_report_en.pdf.
11. Kim JH, Lee TJ, Kim Eugene, Bae H, Kim SJ. Strengthening Transparency of Drug Pricing Negotiation. Seoul National University and NHIS. 2013.
12. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al. Use of generics—a critical cost containment measure for all healthcare professionals in Europe. Pharmaceuticals. 2010;3(8):2470–94.
13. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8(1):7–24.
14. Ministry of Health and Welfare. New drug price policy will be implemented in April 2012. Press release 2012. Available from: http://www.mw.go.kr/front_new/al/sal0301vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&page=183&CONT_SEQ=267283.
15. Simoens S. A review of generic medicine pricing in Europe. GaBI. 2012;1(1):8–12.
16. Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Research. 2013;13(4):469–82.
17. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Research. 2009;9(1):65–83.
18. Woerkom M, Piepenbrink H, Godman B, Metz J, Campbell S, Bennie M, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res. 2012;1(6):527–38.
19. Ministry of Health and Welfare. Pricing and re-pricing standards for reimbursable pharmaceuticals. Notification No. 2015–80. May 29, 2015.
20. Lee HY, Kim JH. Delisting policy reform in South Korea: failed or policy change? Value Health. 2012;15(1):204–12.
21. National Health Insurance Service. Handbook of Drug Expenditure Management Policy of 2014, Seoul, 2014.
22. Yu SY, Yang BM, Kim JH. New anti-rebate legislation in South Korea. Appl Health Econ Health Policy. 2013;11(4):311–8.
23. Law of Pharmaceutical Affairs. Article 76: marketing approval cancellation and suspension of business. No. 25583. September 01, 2014.
24. Presidential Decree of National Health Insurance. Article 18-2: suspension and exclusion of drug reimbursement service. No. 25583. August 20, 2014.
25. Ministry of Health and Welfare (MOHW). Six months after the massive price cuts, drug expenditure savings of 909 billion Korean won. Press Release February 07, 2013. Accessed 17 May 2016.
26. Ministry of Health and Welfare. Certification of innovative pharmaceutical companies and pricing policy: follow-up of the 10th trade investment promotion. Press release July 07, 2016.
27. Phelan M, Cook C. A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients. BMC Infect Dis. 2014;14(Suppl 6):S5.
28. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA. 2014;312(6):593–4.
29. de Bruijn W, Ibanez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, et al. Introduction and utilization of high priced HCV medicines across Europe; implications for the future. Front Pharmacol. 2016;7:197.
30. Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
31. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439–42.14.
32. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA. Cancer drugs in the United States: Justum Pretium–the just price. J Clin Oncol. 2013;31(28):3600–4.
33. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996–1000.
34. Godman B, Abuelkhair M, Vitry A, Abdu S, Bennie M, Bishop I, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBI. 2012;1(2):69–83.
35. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. PharmacoEconomics. 2015;33(9):905–24.